XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
XBiotech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.00−0.12 (-5.66%)
Close on Oct 19, 2026
- Market cap
- $60.98M
- P/E (TTM)
- –
- Dividend yield
- –
XBiotech Inc. revenue by segment
By business segment
By product or service
| Revenue | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing Revenue [Member] | $0 | $0 | $0 | $300.00K | $1.68M | $1.53M | $500.00K | $4.50M | $4.50M | $4.50M | $4.50M | $4.50M | – | -100.0% |
| Clinical Trial Service Revenue [Member] | – | – | – | $0 | $0 | $0 | $0 | $0 | $19.00K | $25.00K | $350.00K | $747.00K | – | – |
By region
From the segment and revenue-disaggregation notes of XBiotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.